3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
14
Phase EARLY_PHASE1
3
Phase 1
3
Phase 3
2
Phase 1/2
2
Phase NA
1
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
3
Gastrointestinal
3
Head & Neck
2
Gynecologic
2
Dermatologic
2
Breast
2
Sarcoma
1
Other solid neoplasm
1
CNS
1
Conditions
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Carboplatin
66
Paclitaxel
54
pembrolizumab
49
Cyclophosphamide
34
Cisplatin
28
Bevacizumab
26
Nivolumab
21
Gemcitabine
18
fludarabine
17
liposomal doxorubicin
15
Topotecan
15
aldesleukin
13
Filgrastim
12
olaparib
11
Interleukin-2
11
Docetaxel
11
Peripheral Blood Stem Cell Transplantation
10
durvalumab
9
Taxes
9
Specimen Handling
9
Oxaliplatin
8
fludarabine phosphate
7
epacadostat
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Injections
7
rucaparib
6
niraparib
6
lenvatinib
6
cemiplimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Metformin
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02755844
2026-05-27
ENDOLA
Hospices Civils de Lyon
Phase 1/2
Completed
35 enrolled